Aptamer Conjugates for Targeted Beta Cell Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring beta cell mass in vivo and delivering therapeutics specifically to beta cells in diabetes are inadequate, relying on indirect measurements and facing challenges with viral vector immunogenicity and safety concerns.
Innovation Solution
Development of RNA aptamers specific for pancreatic islets, conjugated with therapeutic nucleic acids or imaging agents, to target and deliver therapeutic agents directly to beta cells, utilizing aptamer constructs like M12-3773 and 1-717 for precise delivery and imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used to deliver therapeutics to beta cells, then delivery efficiency is improved, but immunogenicity and safety concerns increase
Solution Approach 1:
The patent uses aptamers as intermediary molecules that specifically bind to beta cell surface markers (such as insulin or glucose transporter 2) to mediate the delivery of therapeutic agents. This intermediary approach replaces viral vectors, achieving targeted delivery without triggering immune responses or integration risks.
Solution Approach 2:
The patent employs non-viral, disposable aptamer-based delivery systems that are transient and do not integrate into the genome. These short-lived delivery vehicles provide the necessary therapeutic delivery function without the long-term safety concerns of viral integration or persistent immune activation.
2Ease of operation
If indirect measurements are used to assess beta cell mass, then measurement simplicity is improved, but measurement precision deteriorates
Solution Approach 1:
The patent employs imaging reagents (such as fluorescently labeled aptamers) that bind to beta cells and produce detectable optical signals. This allows direct visualization and quantification of beta cell mass with high precision while maintaining relative simplicity through non-invasive imaging techniques.
Solution Approach 2:
The patent uses aptamers as intermediary probes that specifically recognize and bind to beta cell surface markers. These aptamer-imaging reagent conjugates serve as precise mediators that enable direct detection of beta cells, providing accurate quantification of beta cell mass without relying on indirect proxies like glucose or c-peptide levels.
3Manufacturing precision
If aptamers are used to deliver therapeutics to beta cells, then delivery specificity is improved, but device complexity increases
Solution Approach 1:
The patent combines the aptamer targeting domain with the therapeutic cargo (such as siRNA, mRNA, or small molecules) into a single conjugate construct. This merging of targeting and therapeutic functions into one integrated molecule achieves high delivery specificity while avoiding the complexity of multi-component delivery systems.
Solution Approach 2:
The patent develops a universal aptamer platform that can be conjugated to various therapeutic agents (siRNA, mRNA, small molecules, imaging reagents). This multi-functional approach allows a single aptamer design to serve multiple therapeutic purposes, reducing overall system complexity compared to developing separate targeted delivery systems for each therapeutic modality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables direct measurement of beta cell mass and effective delivery of therapeutics to beta cells, enhancing therapeutic efficacy and safety by avoiding immunogenicity issues associated with viral vectors.
Implementation Method 1
RNA aptamers have emerged as effective delivery vehicles for siRNAs in the treatment of many human diseases because they actively enhance the intracellular accumulation of therapeutic cargo by receptor-mediated internalization
Implementation Method 2
RNA aptamers have emerged as effective delivery vehicles for siRNAs in the treatment of many human diseases because they actively enhance the intracellular accumulation of therapeutic cargo by receptor-mediated internalization or by clathrin-mediated endocytosis
Data Source
AI summary
The present disclosure provides materials and methods for the delivery of therapeutic nucleic cells (and imaging agents) to tissues.